Skip to main content
. 2020 Sep 2;10:14470. doi: 10.1038/s41598-020-71561-2

Figure 2.

Figure 2

(A, B) The influence of liver dysfunction on PFS (A) and OS (B) in patients with diverse cancer types after ICI treatment (unadjusted data). (C, D) Comparison of PFS (C) and OS (D) based on early onset and late onset of liver dysfunction after ICI treatment (unadjusted data). PFS progression-free survival; OS overall survival; ICI immune checkpoint inhibitor).